Miras I, Vázquez-Gutierrez I, Estévez-García P, Muñoz-Galván S*. DNA repair pathways in ovarian cancer: Implications for therapy and resistance. Biomed Pharmacother. 2025. Oct 30;193:118719  * corresponding author

​

Santos-Pereira JM, Carnero A, Muñoz-Galván S*. Integrative multi-omic analysis reveals a PAX8-driven gene network linking tumor stemness to therapy response in ovarian cancer. NAR Genom Bioinform. 2025 Aug 27;7(3):lqaf113. * corresponding author

​

Yang X, Artibani M, Jin Y, Aggarwal A, Zhang Y, Muñoz-Galvan S, Mikhailova E, Rai L, Mukherjee N, Kumar RK, Albukhari A, Ma S, Zhou L, Ahmed AA*, Bayley H*. 3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline. Adv Healthc Mater. 2025 May;14(14):e2404072

​

Miras I, Estévez-García P, Muñoz-Galván S*. Clinical and molecular features of platinum resistance in ovarian cancer. Crit Rev Oncol Hematol. 2024 Sep;201:104434. * corresponding author

​

Muñoz-Galván S*, Verdugo-Sivianes EM, Santos-Pereira JM, Estevez-García P, Carnero A*. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors. J Exp Clin Cancer Res. 2024 Feb 26;43(1):57. * corresponding authors

​

Muñoz-Galván S*, Carnero A*. Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer. Cancers (Basel). 2021. 13(16):4029. * corresponding authors

​

Verdugo-Sivianes EM, Rojas AM, Muñoz-Galván S, Otero-Albiol D, Carnero A. Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells. Theranostics. 2021. 11(7):3452-3471

​

Muñoz-Galván S*, Carnero A*. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells. 2020. 9(6):1402.* corresponding authors

​

Perez M, Garcia-Heredia JM, Felipe-Abrio B, Muñoz-Galván S, Martin-Broto J., Carnero A. Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. Signal Transduct Target Ther. 2020. 5(1):195.

​

Villalonga Á, Ferrer I, Guruceaga E, Cirauqui C, Marrugal Á, Ojeda L, García S, Zugazagoitia J, Muñoz-Galván S, Lopez-Rios F, Montuenga L, Vicent S, Molina-Pinelo S, Carnero A, Paz-Ares L. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. eBiomedicine. 2020. 53:102683.

​

Muñoz-Galván S, Verdugo-Silvianes EM, Felipe-Abrio B, Jiménez-García MP, Suarez-Martinez E, Carnero A. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Mol Cancer. 2020. 19(1):7.

​

Muñoz-Galvan S, Felipe-Abrio B, Garcia-Carrasco M, Dominguez-Piñol J, Suarez-Martinez E, Verdugo-Sivianes EM, Otero-Albiol D, Peinado J, Jimenez-García MP, Estevez P, Carnero A. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. J Exp Clin Cancer Res. 2019. 38(1):234.

​

Muñoz-Galván S, Lucena-Cacace A, Otero-Albiol D, Gomez-Cambronero J, Carnero A. Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment. Oncogene. 2019. 38(8):1309–1323.

​

Lucena-Cacace A, Otero-Albiol D, Jiménez-García MP, Muñoz-Galvan S, Carnero A. NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. Clin Cancer Res. 2018. 24(5):1202-1215.

​

Muñoz-Galván S, García-Rubio M, Ortega P, Ruiz JF, Jimeno S, Pardo B, Gómez-González B, Aguilera A. A new role for Rrm3 in repair of replication-born DNA breakage by sister chromatid recombination. PLoS Genet. 2017. 13(5):e1006781.

​

Muñoz-Galván S, Gutierrez G, Perez M, Carnero A. MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NF kappa B Activation in Breast Cancer. Mol Cancer Ther. 2015. 14(6):1454-65.

​

Estevez-Garcia P, Lopez-Calderero I, Molina-Pinelo S, Muñoz-Galvan S, Salinas A, Gomez-Izquierdo L, Lucena-Cacace A, Felipe-Abrio B, Paz-Ares L, Garcia-Carbonero R, Carnero A. Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. Clin Cancer Res 2013. 19(14):3925-35.

​

Muñoz-Galván S, Jimeno S, Rothstein R, Aguilera A. Histone H3K56 acetylation, Rad52, and non-DNA repair factors control double-strand break repair choice with the sister chromatid. PLoS Genetics 2013. 9(1):e1003237.

​

Muñoz-Galván S, López-Saavedra A, Jackson SP, Huertas P, Cortés-Ledesma F, Aguilera A. Competing roles of DNA end resection and non-homologous end joining functions in the repair of replication-born double-strand breaks by sister-chromatid recombination. Nucleic Acids Res. 2013. 41(3):1669-83. 

​

Muñoz-Galván S, Tous C, Blanco MG, Schwartz EK, Ehmsen KT, West SC, Heyer WD, Aguilera A. Distinct roles of Mus81, Yen1, Slx1-Slx4, and Rad1 nucleases in the repair of replication-born double-strand breaks by sister chromatid exchange. Mol Cell Biol. 2012. 32(9):1592-603.

​

Guijarro MV, Vergel M, Marin JJ, Muñoz-Galván S, Ferrer I, Ramon y Cajal S, Roncador G, Blanco-Aparicio C, Carnero A. p38α limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene 2012. 31(41):4447-59. 

​

Hohl M, Kwon Y, Muñoz-Galván S, Xue X, Tous C, Aguilera A, Sung P, Petrini JH. The Rad50 coiled-coil domain is indispensable for Mre11 complex functions. Nat Struct Mol Biol. 2011. 18(10):1124-31.